Iodine I 131 derlotuximab biotin

Drug Profile

Iodine I 131 derlotuximab biotin

Alternative Names: 131-I chTNT 1/B; 131-I-chTNT-1/B mAb; Cotara; Iodine-131 radiolabelled TNT monoclonal antibody; Monoclonal antibody TNT-1; TNT-1; Tumour necrosis therapy-1

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Peregrine Pharmaceuticals
  • Developer MediPharm Biotech; Peregrine Pharmaceuticals
  • Class Antineoplastics; Iodine radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Lung cancer
  • Phase II Glioblastoma

Most Recent Events

  • 12 Aug 2015 Phase-II development for Glioblastoma is ongoing in USA and India; advancement to phase III is dependent upon securing a partner
  • 06 Dec 2012 Peregrine plans a phase III trial for Glioblastoma (recurrent) in USA
  • 19 Dec 2011 Topline final efficacy data from a phase II trial in Glioblastoma released by Peregrine Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top